Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT) : a randomised, double-blind, placebo-controlled, phase 2 study

Wainberg, ZA; Enzinger, PC; Kang, YK; Qin, SK; Yamaguchi, K; Kim, IH; Saeed, A; Oh, SC; Li, J; Turk, HM; Teixeira, A; Borg, C; Hitre, E; Udrea, AA; Cardellino, GG; Sanchez, RG; Collins, H; Mitra, S; Yang, YS; Catenacci, DVT; Lee, KW

Wainberg, ZA (通讯作者)，Univ Calif Los Angeles, Med Ctr, Dept Med, Los Angeles, CA 90095 USA.

LANCET ONCOLOGY, 2022; 23 (11): 1430

Abstract

Background Outcomes are poor in patients with HER2-negative, advanced gastric or gastro-oesophageal junction adenocarcinomas. In this study, we invest......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索